Nadine Shehab is a senior scientist with the Medication Safety Program in the Division of Healthcare Quality Promotion at the Centers for Disease Control and Prevention (CDC), where she provides leadership in public health surveillance of adverse drug events, identifies policy directions for high-priority CDC medication safety issues, and translates CDC’s public health priorities for medication safety to nationally recognized healthcare quality measures-, standards-, and guidelines-setting organizations and to policy-makers and regulators. She has served as the principal or co-investigator in key epidemiologic studies quantifying and characterizing U.S. hospital emergency department visits andhospitalizations for adverse events from prescription and over-the-counter medications, and dietary supplements, and as one of the principal authors of the Department of Health and Human Services (HHS) National Action Plan for Adverse Drug Event Prevention, which identified anticoagulants as one of three key areas of focus for national medication safety efforts. Since 2013, she has co-led an HHS federal interagency workgroup to address anticoagulant adverse drug events across the department and form inter-departmental and public-private partnerships to advance federal efforts for anticoagulation safety in the areas of surveillance, prevention, oversight, and research.
Dr. Shehab is a clinical pharmacist by training; she completed her post-graduate clinicalpharmacy training at the Cleveland Clinic and University of Michigan Health System and received her Master of Public Health degree from the Johns Hopkins Bloomberg School of Public Health. Prior to joining CDC in 2006, Dr. Shehab was a clinical pharmacistin drug information and clinical assistant professor at the University of Michigan Health System and College of Pharmacy. She is currently based in the Washington DC area, where she leads several of CDC’s Medication Safety Program’s engagements with federal partners, such as the Centers for Medicare & Medicaid Services and the Food and Drug Administration, and serves as the CDC liaison to various medication safety standards-setting committees and expert panels to help translate CDC public health data on anticoagulation safety into patient safety policies.